Sensei Biotherapeutics Inc 2025年季度报告

(Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 Sensei Biotherapeutics, Inc.(Exact name of Registrant as specified in its Charter) Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Actof 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subjectto such filing requirements for the past 90 days.YES☒NO☐ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required tosubmit such files).YES☒NO☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).YES☐NO☒The number of shares of Registrant’s Common Stock outstanding as of May 2, 2025 was25,208,068. Table of Contents PART IFINANCIAL INFORMATIONItem 1.Condensed Consolidated Financial Statements (Unaudited)1Condensed Consolidated Balance Sheets as of March 31, 2025 and December 31, 20241Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months endedMarch 31, 2025 and 20242Condensed Consolidated Statements of Common Stock and Stockholders’ Equity for the three months endedMarch 31, 2025 and 20243Condensed Consolidated Statements of Cash Flowsfor the three months ended March 31, 2025 and 20244Notes to Condensed Consolidated Financial Statements5Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations15Item 3.Quantitative and Qualitative Disclosures About Market Risk23Item 4.Controls and Procedures23 PART IIOTHER INFORMATIONItem 1.Legal Proceedings24Item 1A.Risk Factors24Item 2.Unregistered Sales of Equity Securities and Use of Proceeds64Item 3.Defaults Upon Senior Securities65Item 4.Mine Safety Disclosures65Item 5.Other Information65Item 6.Exhibits65Signatures66 SENSEI BIOTHERAPEUTICS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(Unaudited)(In thousands, except share and per share data) For the Three MonthsEnded March 31,20252024Operating expenses:Research and development$3,725$4,917General and administrative3,5493,813Total operating expenses7,2748,730Loss from operations(7,274)(8,730)Other income (expense):Interest income405768Interest expense(13)(28)Gain on asset disposal20—Other expense, net(2)(2)Net loss(6,864)(7,992)Net loss per common share, basic and diluted$(0.27)$(0.32)Weighted-average number of shares used in computing net loss per common share,basic and diluted25,192,36325,049,111Comprehensive loss:Net loss$(6,864)$(7,992)Other comprehensive items:Unrealized gain on marketable securities772Total other comprehensive income772Total comprehensive loss$(6,857)$(7,920) SENSEI BIOTHERAPEUTICS, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited)(In thousands) SENSEI BIOTHERAPEUTICS,INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited) 1. ORGANIZATION AND OPERATIONS Business Sensei Biotherapeutics, Inc. (the “Company” or “Sensei”), a clinical-stage biotechnology company, was incorporated in 1999as a Maryland corporation until being incorporated in Delaware on December 1, 2017. The Company is focused on the discoveryand development of next-generation therapeutics for cancer patients. Liquidity and capital resources Since its inception, the Company has devoted substantially all of its resources to advancing development of its portfolio ofprograms, establishing and protecting its intellectual property, conducting research and development activities, organizing andstaffing the Company, business planning, raising capital and providing general and administrative support for these operations. Asa result, the Company has incurred substantial losses and had a net loss of$6.9millionfor the three months ended March 31, 2025.As of March 31, 2025, the Company had an accumulated deficit of$268.9million. The Company expects to generate operatinglosses and negative operating cash flows for the foreseeable future, and as a result the Company’s liquidity position continues totighten with the passage of time.